538 related articles for article (PubMed ID: 25458015)
1. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
Hatipoglu G; Hock SW; Weiss R; Fan Z; Sehm T; Ghoochani A; Buchfelder M; Savaskan NE; Eyüpoglu IY
Cancer Sci; 2015 Feb; 106(2):160-70. PubMed ID: 25458015
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
[TBL] [Abstract][Full Text] [Related]
4. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Sehm T; Fan Z; Ghoochani A; Rauh M; Engelhorn T; Minakaki G; Dörfler A; Klucken J; Buchfelder M; Eyüpoglu IY; Savaskan N
Oncotarget; 2016 Jun; 7(24):36021-36033. PubMed ID: 27074570
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of vascular endothelial growth factor and platelet-derived growth factor signaling: effects on the angiogenesis, microcirculation, and growth of orthotopic malignant gliomas.
Farhadi MR; Capelle HH; Erber R; Ullrich A; Vajkoczy P
J Neurosurg; 2005 Feb; 102(2):363-70. PubMed ID: 15739567
[TBL] [Abstract][Full Text] [Related]
7. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
[TBL] [Abstract][Full Text] [Related]
8. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide.
Zhou Q; Guo P; Gallo JM
Clin Cancer Res; 2008 Mar; 14(5):1540-9. PubMed ID: 18316579
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD.
Saito Y; Tanaka Y; Aita Y; Ishii KA; Ikeda T; Isobe K; Kawakami Y; Shimano H; Hara H; Takekoshi K
Am J Physiol Endocrinol Metab; 2012 Mar; 302(6):E615-25. PubMed ID: 21878661
[TBL] [Abstract][Full Text] [Related]
10. NDRG1 overexpressing gliomas are characterized by reduced tumor vascularization and resistance to antiangiogenic treatment.
Broggini T; Wüstner M; Harms C; Stange L; Blaes J; Thomé C; Harms U; Mueller S; Weiler M; Wick W; Vajkoczy P; Czabanka M
Cancer Lett; 2016 Oct; 380(2):568-576. PubMed ID: 26297987
[TBL] [Abstract][Full Text] [Related]
11. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis.
Catena R; Luis-Ravelo D; Antón I; Zandueta C; Salazar-Colocho P; Larzábal L; Calvo A; Lecanda F
Cancer Res; 2011 Jan; 71(1):164-74. PubMed ID: 21097719
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis.
Bousquet G; Varna M; Ferreira I; Wang L; Mongiat-Artus P; Leboeuf C; de Bazelaire C; Faivre S; Bertheau P; Raymond E; Germain S; Janin A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1183-93. PubMed ID: 24061866
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel operates anti-metastatic and cytotoxic via apoptosis induction and stalls brain tumor angiogenesis.
Ghoochani A; Hatipoglu Majernik G; Sehm T; Wach S; Buchfelder M; Taubert H; Eyupoglu IY; Savaskan N
Oncotarget; 2016 Jun; 7(25):38306-38318. PubMed ID: 27203678
[TBL] [Abstract][Full Text] [Related]
17. Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model.
Zhou Q; Gallo JM
Neuro Oncol; 2009 Jun; 11(3):301-10. PubMed ID: 18971416
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
19. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
